AHCO AdaptHealth Corp. Insider Trading

10% owner Richard Cashin buys 447.8K shares at $9.91 across 2 transactions, raising stake to 16.31M shares

Richard Cashin, a 10% owner of AdaptHealth Corp., executed 2 separate purchases totaling 447,827 shares for $4,438,927.53 at a blended average price of $9.91 on March 19-20, 2026, increasing his post-transaction holdings to 16,312,698 shares. The current price of $10.37 sits -4.3% below the 52-week high of $10.84, offering a modest premium relative to the $9.91 purchase price but no exceptional valuation context. Cashin's cross-ticker track record shows 2 prior sells with a 90d well-timed rate of 100%, but his prior AHCO trades (3 buys on March 10-12, outcome not yet measurable) provide insufficient evidence of a sustained pattern at this ticker. The company's full-year net income was negative, offsetting otherwise stable quarterly revenue of $820.3M with -0.5% annual growth and a $1.4B market cap, suggesting a mature business without growth momentum.

10% Owner Cashin buys 2,046,691 shares for $19.9M across 3 days at $9.73; holdings jump to 15.86M; cluster buy pattern observed

Richard M. Cashin Jr., a 10% owner, executed 3 separate open-market purchases totaling 2,046,691 shares (2.05M shares) for $19,912,147.84 ($19.9M) over March 10–12, 2026, at a blended average price of $9.73, raising his holdings from 13,818,180 shares to 15,864,871 shares—a net increase of +14.8%. The timing coincides with a 52-week low around $7.33 and a current price of $9.75, placing the blended transaction price within the lower-to-middle portion of the 52-week range ($7.33–$10.84), and the stock is currently down -10.1% from its 52-week high and -8.4% over the trailing 30 days. The acquisition occurs during a period of company headwinds: AdaptHealth is unprofitable on an annual basis despite generating $820.3M in quarterly revenue and $24.5M net income in the latest quarter, with annual revenue growth at -0.5%. A cluster buy pattern—2 other insiders also purchased within the past 14 days—is visible alongside Cashin's purchases. The magnitude of his commitment (a $19.9M outlay increasing his stake by roughly one-seventh) during a downturn period, combined with the simultaneous insider activity, warrants investor attention to the underlying drivers and near-term capital allocation signals.

Director WOLF DALE B buys 8.0K shares of AHCO at $8.96; holdings now 104.2K (+8.3%)

Director WOLF DALE B purchased 8,000 shares at $8.96 on 2026-02-27, increasing his holdings from 96,235 to 104,235 shares. His cross-ticker track record shows 3 prior open-market buys with avg 30d return +21.7%, avg 90d return +22.0%, and 100.00% win rate, suggesting a history of well-timed acquisitions. However, context tempers this signal: AdaptHealth's fundamentals are mixed—the company was unprofitable over its most recent full fiscal year with annual revenue growth of -0.5%, though it posted $24.5M in net income and $820.3M in revenue in the latest quarter. The stock trades at $9.40 currently, -17.4% from its 52-week high and -6.5% over the past 30 days, positioning this purchase at a relatively depressed point in the stock's recent range, though this alone does not establish conviction or timing. The magnitude of the position increase (+8.3%) is material and represents meaningful capital deployment into a name with execution headwinds.

CLO Richard W. Rew buys 5,000 AHCO shares at $8.91; stock down 19.6% from 52-week high

Rew Richard W. II, the Chief Legal Officer and General Counsel of AdaptHealth Corp., purchased 5,000 shares at $8.91 on 2026-02-26, increasing his holdings from 102,097 to 107,097 shares. The purchase occurs while the stock trades at $9.15, down 19.6% from its 52-week high of $11.38 and down 4.9% over the prior 30 days. This is a modest absolute purchase ($44,550.00 total value) representing a 4.9% increase to his existing position. The broader context shows the company generated $820,314,000.00 in latest quarterly revenue but reported negative full-year net income on an annual basis, with revenue growth of -0.5% year-over-year. An insider buy at a depressed price point by a senior legal officer may warrant monitoring, though the transaction size relative to both his existing holdings and the company's $1.2B market cap remains limited in scope.

AdaptHealth CTO Albert Prast sold 135,443 shares (42.8% of holdings) at $10.41; stock now $11.48, up 32.6% in 30 days

CTO Prast divested 135,443 shares for $1,409,961.63, reducing his stake from 316,526 to 181,083 shares—a significant 42.8% reduction in his pre-transaction holdings. The sale occurred at $10.41 on 2024-03-04, while the stock currently trades at $11.48 and has gained 32.6% over the past 30 days, suggesting the insider sold before a material near-term rally. Prast's cross-ticker track record shows 2 prior sells with a 90-day well-timed rate of 100%, and his same-ticker history at AHCO (2 prior sells on 2023-08-10) both registered negative 90-day returns of -23.9% and -27.7%, indicating consistent pattern recognition preceding price declines at the 90-day horizon. However, the current price action—32.6% appreciation in 30 days following this March sale—diverges from his established timing pattern, warranting examination of whether fundamental shifts (the company was unprofitable over its most recent full fiscal year, though latest quarter revenue is $806.0M with net income of $19.4M) or other factors altered the investment thesis.